Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial

Abstract Background The recommended treatment for patients with non-metastatic muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). Following NAC, 20–40% of patients experience a complete pathological response (pCR) in the RC specimen and these patient...

Full description

Bibliographic Details
Main Authors: F. J. Hinsenveld, B. J. Noordman, J. L. Boormans, J. Voortman, G. J. L. H. van Leenders, S. L. van der Pas, S. C. van Beek, D. E. Oprea-Lager, A. N. Vis
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Cancer
Subjects:
Bladder cancer
Cancer biomarkers
Cystectomy
Neoadjuvant chemotherapy
Residual tumour
Bladder-sparing
Online Access:https://doi.org/10.1186/s12885-021-08840-2

Internet

https://doi.org/10.1186/s12885-021-08840-2

Similar Items